FAYETTEVILLE, AR, United States
FAYETTEVILLE, AR, United States
SEARCH FILTERS
Time filter
Source Type

Arya S.K.,Institute of Microelectronics, Singapore | Pui T.S.,Institute of Microelectronics, Singapore | Wong C.C.,Institute of Microelectronics, Singapore | Kumar S.,Sfc Fluidics, Llc | Rahman A.R.A.,Institute of Microelectronics, Singapore
Langmuir | Year: 2013

In the present work, the effect of a surface modification protocol along with the electrode size has been investigated for developing an efficient, label-free electrochemical biosensing method for diagnosis of traumatic brain injury (TBI) biomarkers. A microdisk electrode array (MDEA) and a macroelectrode with a comb structure (MECS) were modified with an anti-GFAP (GFAP = glial fibrillary acidic protein) antibody using two protocols for optimum and label-free detection of GFAP, a promising acute-phase TBI biomarker. For the MDEA, an array of six microdisks with a 100 μm diameter and, for the MECS, a 3.2 mm × 5.5 mm electrode 5 μm wide with 10 μm spaced comb fingers were modified using an optimized protocol for dithiobis(succinimidyl propionate) (DSP) self-assembled monolayer formation. Anti-GFAP was covalently bound, and the remaining free DSP groups were blocked using ethanolamine (Ea). Sensors were exposed to solutions with different GFAP concentrations, and a label-free electrochemical impedance spectroscopy (EIS) technique was used to determine the concentration. EIS results confirmed that both types of Ea/anti-GFAP/DSP/Au electrodes modified with an optimized DSP-based protocol can accurately detect GFAP in the range of 1 pg mL-1 to 100 ng mL-1 with a detection limit of 1 pg mL-1. However, the cross-use of the MDEA protocol on the MECS and vice versa resulted in very low sensitivity or poor signal resolution, underscoring the importance of proper matching of the electrode size and type and the surface modification protocol. © 2013 American Chemical Society.


Das C.,Sfc Fluidics, Llc | Wang G.,Sfc Fluidics, Llc | Payne F.,Sfc Fluidics, Llc
Sensors and Actuators, A: Physical | Year: 2013

Magnetohydrodynamic pumping provides a unique opportunity to mobilize fluids inside a channel using very low power and without employing any external moving parts. In this paper, we illustrate certain unique applications of these pumps such as sample injection, fluid flow in packed bed, and on-chip assay development, all of which are relevant to point-of-care diagnostic device design and fabrication. A linear flow velocity of 5 cm/min was obtained using four on-board pumps in a closed loop of circumferential track length of 10 cm (channel cross section of 0.5 mm × 0.5 mm), whereas it dropped to 1.8 mm/min in a packed bed column operated by a single pump. Finally, these pumps were integrated with silicon immunoassay chips to evaluate the feasibility of transporting electro active species with these pumps from source to electrochemical detection site. © 2013 Elsevier B.V. All rights reserved.


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 215.00K | Year: 2015

DESCRIPTION provided by applicant The Specific Aim of this Phase I project is to prove the feasibility of using SFC Fluidicsandapos patented microfluidic pumping technology to develop the RatPump a low cost disposable battery operated implantable on demand tether free drug delivery system The RatPump will allow real time wirelessly controlled delivery of drugs and therapeutics to animals for addiction and behavior research models This implantable pumping system will have substantially improved operational capacities at a much lower cost as compared to current tethered and non tethered drug delivery systems During the last three months of Phase I the RatPump will be implanted and tested in rats at the McLean Psychiatric Hospital at Harvard University The following Phase I Tasks are designed to prove feasibility of this Specific Aim Task Integration of microfluidic components into an implantable on demand drug delivery device SFC Fluidics Months Task Demonstration of controlled fluid movement ex vivo from the drug delivery system using specified test protocol SFC Fluidics Months Task Demonstration of use of implanted RatPump showing ability to deliver drugs on demand and remotely Harvard McLean Medical School Months Phase II will focus on modifying the Phase I RatPump prototype based on the results of Phase I testing and iterative advanced development By the end of Phase II SFC Fluidics will have a final design RatPump system that will deliver on demand doses of drugs and therapeutics with an accuracy of The focus of our subcontractor in Phase II will be to improve his drug addiction models as enabled by the RatPump and to provide those data in publications scientific conferences and collaborations in order to facilitate the use of the RatPump toward the advancement of drug addiction models in other laboratories PUBLIC HEALTH RELEVANCE A low cost disposable quick response programmable or response dependent micropumping system like RatPumpTM would have widespread use in behavioral pharmacology and veterinary medicine This drug delivery device concept targets preclinical animal model research as well as veterinary therapy as market applications With additional funding this system could be adapted for implantable drug delivery needs in humans as well


Grant
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 225.00K | Year: 2016

Development of a Low Profile Dual Hormone Patch Pump with Novel Occlusion Sensor Project Summary The Specific Aim of this project is to develop a discrete low profile dual hormone drug delivery system using SFC Fluidics enabling microfluidic technologies A dual ePump will be developed in which a single ePump body will independently and accurately deliver both insulin and glucagon from two separate reservoirs Latching micro valve sets will independently and safely control the delivery of each hormone and a flow confirmation sensor will identify dosing errors from either occlusions or electrical mechanical failures Phase I will see the development of an early prototype with control system and a dosing accuracy of for nL to L dosing volumes will be targeted During Phase II SFC Fluidics will work closely with clinicians and drug formulation glucose sensor and control algorithm developers to develop a robust and reliable artificial pancreas Project Narrative The proposed dual drug delivery system will have the necessary safety features and low dose accuracy to meet the need for insulin and glucagon dual hormone delivery to type diabetics including children and adolescents to greatly improve the quality of life for this significant and growing at risk group


Grant
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 165.78K | Year: 2011

DESCRIPTION (provided by applicant): Portable brain injury biomarker detection system with integrated microdialysis probe Project summary/Abstract: This SBIR application aims to integrate microdialysis with an effective, miniature pumping system and adetection system for analyzing different biomarkers in real-time and without user intervention. An integrated portable device consisting of SFC Fluidics' proprietary ePump(R), snap-on magnetic latches for rapid fluidic connection, a reagent reservoir and amicrofluidic detection system will be developed. This system will facilitate real time continuous monitoring of pathological biomarkers, which in turn helps in better patient management over the course of healing/therapy. The focus of this SBIR is on monitoring Traumatic Brain Injury (TBI) sequelae with a microdialysis based system using a set of low molar mass biomarkers and a leading large molecule (protein) biomarker. In Phase I, commercially-available ELISA kits will be incorporated into SFC Fluidics integrated microdialysis and fluid handling system. The Phase II focus will be on development of a single prototype system that can quantify multiple TBI biomarkers. Phase I Research Plan Specific Aim: Design and engineer brain injury biomarker detection system with integrated microdialysis probe Task 1: Design and fabricate ePump driven integrated flow system Task 2: Detection of small molecule brain injury biomarkers Task 3: Detection of large molecule brain injury biomarker PUBLIC HEALTH RELEVANCE:An estimated 1.7 million Traumatic Brain injury (TBI) cases are reported every year in United States with 80.7 percent of them resulting in emergency department visits. There is an urgent need for development of a portable, microdialysis system with in-built analyzer which will help in rapid and continuous diagnosis of the state of health of a patient with TBI. Early and timely diagnosis of the pathological condition will help a doctor to take remedial actions and improve the quality of care of the patient while greatly mitigating long-term complications.


Sfc Fluidics, Llc | Entity website

Barry Ginsberg, M.D ...


Sfc Fluidics, Llc | Entity website

Greg Lamps-VP, Product RealizationVP/Director at Facet Tech, IdeaMed & Coapt SystemsSenior Engineer, Diamler-BenzMBA, MS & BS Mechanical Engineering, Stanford University


Sfc Fluidics, Llc | Entity website

Healthcare Industry Leader Anthony Cruz Joins SFC Fluidicsas Chief Executive OfficerFayetteville, AR September 1, 2012 SFC Fluidics has begun its next phase of commercialization through the appointment of a new CEO, Anthony (Tony) Cruz. He brings to the Company a breadth of over twenty years of sales, marketing, and business development experience within the medical device and biotech sectors ...


Sfc Fluidics, Llc | Entity website

SFC Fluidics Developing Smaller, Disposable Insulin Patch PumpsArkansas company and strategic partner secure over $2 million to help commercialize automatic insulin pump and suite of groundbreaking microfluidics devices.FAYETTEVILLE, Ark ...


Sfc Fluidics, Llc | Entity website

Loading Sfc Fluidics, Llc collaborators
Loading Sfc Fluidics, Llc collaborators